NASDAQ: VBIO · Life Sciences · 14 alerts · CIK 1787740
Share price
$0.5290Close, Nov 16
Market cap
$11.7M
Shares outstanding
22.19MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Valion Bio, Inc. filings on SEC EDGAR ↗
Valion Bio held a special meeting of stockholders on November 12, 2026, where shareholders approved three key proposals. These included granting the board discretionary authority to effect a reverse stock split (ratio between 1-for-2 and 1-for-12) and amending the 2021 Equity Incentive Plan to increase the authorized share reserve by 272,000 shares.
Valion Bio, Inc. completed a $700,000 closing under its existing Series B Preferred Purchase Agreement with 3i, LP, issuing 700 shares of Series B Non-Voting Convertible Preferred Stock and warrants to purchase 21,539 shares of common stock. As part of the agreement, the company committed to filing a registration statement for the resale of the underlying common shares within 30 days and extended the outside date for future closings to December 9, 2027.
Lisa Wolf has voluntarily resigned from her positions as President, Chief Operating Officer, and Chief Financial Officer of Valion Bio, Inc. Her resignation is scheduled to become effective on December 11, 2026.
Valion Bio, Inc. terminated the employment of Melinda Lackey, General Counsel and Senior Vice President of Legal Affairs, effective October 30, 2026. Under a separation agreement, she will receive a lump-sum cash severance payment of $26,750 and temporary COBRA premium coverage.
Valion Bio announced positive final safety data from a NIAID-funded study of its lead biologic candidate, Entolimod, conducted by the Armed Forces Radiobiology Research Institute (AFRRI). The study found no evidence of treatment-related toxicity or hematologic disruption in mice, supporting the advancement to a fully funded therapeutic study evaluating survival and gastrointestinal recovery following radiation exposure.
Valion Bio, Inc. entered into side letters to issue Series B and Series C Preferred Shares and warrants for total proceeds of approximately $4.77 million. The transaction includes a $50,000 Series B closing with 3i, LP and a $4.72 million Series C closing with existing purchasers, part of which satisfies overdue cash true-up obligations.
Valion Bio has received unsolicited acquisition inquiries from third parties regarding its wholly owned CDMO subsidiary, Velocity Bioworks. The company has retained an investment bank to evaluate strategic options, including a potential sale, while prioritizing the retention of manufacturing rights for its lead drug candidate, Entolimod.
Interim CEO Dean Zikria released a 30-day strategic assessment focusing on advancing the Entolimod clinical pipeline and commercializing the company's Velocity Bioworks CDMO unit. The company is exploring strategic partnerships and licensing deals to bridge the gap between its scientific assets and current market valuation.
Valion Bio's subsidiary, Velocity Bioworks, successfully completed an initial feasibility evaluation of LarmorBio's BioScan-NMR platform, achieving a milestone in their partnership. The evaluation demonstrated that NMR measurements can track microbial growth in real-time, supporting the development of non-invasive bioprocess monitoring for biologics manufacturing.
Valion Bio highlighted the capabilities of its wholly owned CDMO subsidiary, Velocity Bioworks, to support biotechnology companies seeking domestic U.S.-based manufacturing. The update follows the implementation of Section 232 pharmaceutical tariffs, positioning Velocity's San Antonio facility as a strategic option for early-phase clinical drug substance manufacturing.
Valion Bio, Inc. entered into a letter agreement with 3i, LP to issue 50 shares of Series B Non-Voting Convertible Preferred Stock and warrants for 1,539 shares of common stock. The transaction resulted in gross proceeds of $50,000 as part of an ongoing securities purchase agreement. The warrants have an initial exercise price of $2.5520 per share.
Valion Bio issued a press release highlighting the appointment and strategic goals of its new Board Chair, Thomas Jensen, who joined the board in September 2026. Jensen, the current CEO of Allarity Therapeutics, will focus on advancing the company's lead candidate, Entolimod, as a medical countermeasure for acute radiation syndrome. The company is leveraging Jensen's experience in biotech turnarounds to align strategic priorities with disciplined resource allocation.
Valion Bio announced the successful completion of formulation work for a novel oral mucosal version of its radiation protection biologic, Entolimod, using Shear Kershman Laboratories' BioViscid platform. This milestone creates a potential needle-free delivery pathway that could significantly expand the addressable market for radiological emergency deployment. The company plans to move into studies testing systemic delivery into the bloodstream next.
Valion Bio, Inc. appointed Dean Zikria as Interim Chief Executive Officer, effective September 22, 2026, succeeding Sheryle Bolton who stepped down from the Board. Mr. Zikria, an existing director, will receive a monthly consulting fee of $23,333 and up to 100,000 restricted stock units as part of his interim leadership agreement.